Outcomes of liver transplantation patients infected with COVID-19: pandemic hospital experience from Turkey DOI Creative Commons
Taner Akyol, Tolga Düzenli

Journal of Health Sciences and Medicine, Год журнала: 2023, Номер 6(6), С. 1154 - 1157

Опубликована: Окт. 29, 2023

Aims: There are conflicting results for the course of disease and mortality rates liver transplantation patients infected with COVID-19. In this study, we aimed to present outcomes our transplant who were hospitalized followed up in tertiary hospital, which served as a pandemic hospital Methods: Patients diagnosis COVID-19 between March 1, 2020 2022 Sancaktepe Şehit Prof. Dr. İlhan Varank Training Research Hospital Feriha Öz Pandemic included. retrospective observational clinical data patients, need intensive care hospitalization, recorded by computer system. The relationships analyzed SPSS v20.0. Results: 25996 28 them history transplantation. Ages ranged from 18 73, median age 52. 82.1% male 17.9% female. Intensive unit hospitalization rate was 25% 14.3%. according groups revealed that all women under 50 (p=0.008) deceased over (p=0.044). Conclusion: Mortality requirements chronically immunosuppressed infection similar general population. Complete immunosuppression withdrawal should not be urged

Язык: Английский

The Impact and Evolution of COVID-19 on Liver Transplant Recipients Throughout the Pandemic “Waves” in a Single Center DOI Creative Commons
Clara Fernández Fernández,

Blanca Otero Torrón,

Mercedes Bernaldo de Quirós Fernández

и другие.

Viruses, Год журнала: 2025, Номер 17(2), С. 273 - 273

Опубликована: Фев. 16, 2025

Liver transplant recipients (LTRs) have been considered a population group that is vulnerable to COVID-19 as they are chronically immunosuppressed patients with frequent comorbidities. This study describes the course of SARS-CoV-2 disease from February 2020 December 2023 along seven pandemic "waves". We carried out an observational on 307 cases in cohort LTRs aim evaluating changes characteristics over time and determining risk factors for severe COVID-19. An older age serum creatinine level ≥ 2 mg/dL were found be hospital admission respiratory failure. The use calcineurin inhibitors was protective factor death, hospitalization, failure One hundred percent who died (N = 12) mycophenolate mofetil, which determinant Azathioprine associated intensive care unit (ICU) invasive mechanical ventilation (IMV). Vaccination failure, mortality. rate higher during first five waves, peak 57.14%, highest mortality (21.43%) occurred fourth wave. IMV ICU rates did not show significant differences across periods studied.

Язык: Английский

Процитировано

2

A mid‑pandemic night's dream: Melatonin, from harbinger of anti‑inflammation to mitochondrial savior in acute and long COVID‑19 (Review) DOI Creative Commons
Ioannis Lempesis, Vasiliki Georgakopoulou, Russel J. Reíter

и другие.

International Journal of Molecular Medicine, Год журнала: 2024, Номер 53(3)

Опубликована: Янв. 26, 2024

Coronavirus disease 2019 (COVID‑19), a systemic illness caused by severe acute respiratory distress syndrome 2 (SARS‑CoV‑2), has triggered worldwide pandemic with symptoms ranging from asymptomatic to chronic, affecting practically every organ. Melatonin, an ancient antioxidant found in all living organisms, been suggested as safe and effective therapeutic option for the treatment of SARS‑CoV‑2 infection due its good safety characteristics broad‑spectrum antiviral medication properties. Melatonin is essential various metabolic pathways governs physiological processes, such sleep‑wake cycle circadian rhythms. It exhibits oncostatic, anti‑inflammatory, anti‑aging properties, exhibiting promise use numerous disorders, including COVID‑19. The preventive effects melatonin have widely explored number conditions well‑established experimental ischemia/reperfusion investigations, particularly coronary heart stroke. Clinical research evaluating COVID‑19 shown improved outcomes, reduced hospitalization durations; however, trials are small. can alleviate mitochondrial dysfunction COVID‑19, improve immune cell function provide However, potential remains underexplored funding limitations thus further investigations required.

Язык: Английский

Процитировано

5

The parallel lives of pandemics: COVID‑19 and obesity DOI Open Access
Vasiliki Georgakopoulou, Ioannis Lempesis, Demetrios�� Spandidos

и другие.

Experimental and Therapeutic Medicine, Год журнала: 2024, Номер 27(5)

Опубликована: Март 6, 2024

The present article discusses the interconnectedness of coronavirus disease 2019 (COVID‑19) and obesity as global health crises. similarities between two conditions are highlighted; these include shared risk factors comorbidities, impact on immune system. also mentions challenges faced in combating both pandemics, including misinformation prejudice against obesity. It development therapeutic medications vaccines for COVID‑19 potential injectable incretin analogues weight loss. Socioeconomic issues addressed, with being more prevalent lower socioeconomic groups cost treatments a barrier those need. emphasizes need comprehensive sustainable solutions, public interventions, education, policy changes equitable distribution resources, to address

Язык: Английский

Процитировано

1

Impact of COVID-19 on liver transplant recipients: A nationwide cohort study evaluating hospitalization, transplant rejection, and inpatient mortality DOI
Faisal Inayat, Pratik Patel, Hassam Ali

и другие.

World Journal of Transplantation, Год журнала: 2024, Номер 14(2)

Опубликована: Июнь 13, 2024

BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic has posed a major public health concern worldwide. Patients with comorbid conditions are at risk of adverse outcomes following COVID-19. Solid organ transplant recipients concurrent immunosuppression and comorbidities more susceptible to severe COVID-19 infection. It could lead higher rates inpatient complications mortality in this patient population. However, studies on liver (LT) have yielded inconsistent findings. AIM To evaluate the impact hospital-related among LT United States. METHODS We conducted retrospective cohort study using 2019–2020 National Inpatient Sample database. primary hospitalizations secondary diagnosis were identified International Classification Diseases, Tenth Revision coding system. included trends before during pandemic. Secondary comparative rejection recipients. RESULTS A total 15720 hospitalized included. Approximately 0.8% patients had In both cohorts, median admission age was 57 years. linear for did not differ significantly (P = 0.84). frequency in-hospital increased from 1.7% 4.4% between January December 2020. Compared pre-pandemic period, association noted pandemic, an odds ratio (OR) 1.69 [95% confidence interval (CI): 1.55-1.84), P < 0.001]. rejections 0.2% 3.6% than [OR: 1.53 (95%CI: 1.26-1.85), CONCLUSION hospitalization comparable

Язык: Английский

Процитировано

1

Outcomes of COVID-19 in 24 hospitalized liver transplant recipients: an observational study DOI Creative Commons
Amir M. Sadeghian,

Mohsenreza Mansourian,

Mitra Ranjbar

и другие.

BMC Infectious Diseases, Год журнала: 2024, Номер 24(1)

Опубликована: Сен. 20, 2024

Although liver transplant (LT) recipients are considered a population at risk of severe features coronavirus disease 2019 (COVID-19), data in this regard scarce and controversial. In study, we reported the outcome 24 cases LT who were hospitalized due to COVID-19 investigated role-playing factors severity disease.

Язык: Английский

Процитировано

0

Outcomes of liver transplantation patients infected with COVID-19: pandemic hospital experience from Turkey DOI Creative Commons
Taner Akyol, Tolga Düzenli

Journal of Health Sciences and Medicine, Год журнала: 2023, Номер 6(6), С. 1154 - 1157

Опубликована: Окт. 29, 2023

Aims: There are conflicting results for the course of disease and mortality rates liver transplantation patients infected with COVID-19. In this study, we aimed to present outcomes our transplant who were hospitalized followed up in tertiary hospital, which served as a pandemic hospital Methods: Patients diagnosis COVID-19 between March 1, 2020 2022 Sancaktepe Şehit Prof. Dr. İlhan Varank Training Research Hospital Feriha Öz Pandemic included. retrospective observational clinical data patients, need intensive care hospitalization, recorded by computer system. The relationships analyzed SPSS v20.0. Results: 25996 28 them history transplantation. Ages ranged from 18 73, median age 52. 82.1% male 17.9% female. Intensive unit hospitalization rate was 25% 14.3%. according groups revealed that all women under 50 (p=0.008) deceased over (p=0.044). Conclusion: Mortality requirements chronically immunosuppressed infection similar general population. Complete immunosuppression withdrawal should not be urged

Язык: Английский

Процитировано

0